Quarterly ResultMay 11, 2026, 04:17 PM
Elicio Q1 Net Loss $(11.8)M; EPS $(0.65); AMPLIFY-7P DFS mid-2026
AI Summary
Elicio Therapeutics reported a Q1 2026 net loss of $(11.8) million, with net loss per share improving to $(0.65). The company anticipates the event-driven primary disease-free survival analysis for its Phase 2 AMPLIFY-7P study in pancreatic cancer mid-year 2026, noting fewer disease progressions and deaths than projected to date. Elicio raised $13.0 million through its at-the-market program, extending its cash runway into Q4 2026, beyond the expected DFS data readout.
Key Highlights
- Q1 2026 net loss was $(11.8) million, compared to $(11.2) million in Q1 2025.
- Net loss per share improved to $(0.65) in Q1 2026 from $(0.87) in Q1 2025.
- R&D expenses decreased to $6.8 million in Q1 2026 from $7.8 million in Q1 2025.
- G&A expenses increased to $3.8 million in Q1 2026 from $3.0 million in Q1 2025.
- Cash and cash equivalents were $14.9 million as of March 31, 2026.
- Raised $13.0 million net proceeds via ATM program in Q1/Q2 2026.
- Anticipate AMPLIFY-7P Phase 2 DFS analysis mid-year 2026.
- Projected cash runway extends into Q4 2026, past DFS data.